The interleukin-3 receptor alpha chain (IL-3Rα), more commonly referred to as CD123, is
widely overexpressed in various hematological malignancies, including acute myeloid …

In spite of consistent progress at the level of basic research and of clinical treatment, acute
myeloid leukemia (AML) still represents an unmet clinical need for adult and pediatric …

Recent studies indicate that abnormalities of the alpha-chain of the interleukin-3 receptor (IL-
3RA or CD123) are frequently observed in some leukemic disorders and may contribute to …

The α chain of interleukin 3 receptor (IL-3Rα or CD123), together with the common β (βc)
subunit, forms a high-affinity IL-3R with biological function. In recent years, emerging …

The current treatment of relapsed or refractory AML is associated with low rates of complete
response (CR) and considerable complications. As a result, only a minority of patients (pts) …

Acute myeloid leukemia (AML) is a biologically heterogeneous group of related diseases in
urgent need of better therapeutic options. Despite this heterogeneity, overexpression of the …

Acute myeloid leukemia (AML) blasts express high levels of interlekin-3 (IL-3) receptor-α
(CD123). CSL360 is a recombinant, chimeric immunoglobulin G1 (IgG1), anti-CD123 …

Purpose: Despite promising clinical activity, T-cell–engaging therapies including T-cell
bispecific antibodies (TCB) are associated with severe side effects requiring the use of step …

Targeted eradication of transformed or otherwise dysregulated cells using monoclonal
antibodies (mAb), antibody–drug conjugates (ADC), T cell engagers (TCE), or chimeric …

Background: CD47 is a transmembrane protein ubiquitously expressed in human cells.
CD47 is overexpressed in various malignancies and is correlated with negative prognosis in …